BioNTech (UK) Performance
| 0A3M Stock | USD 120.00 0.45 0.38% |
On a scale of 0 to 100, BioNTech holds a performance score of 10. The firm shows a Beta (market volatility) of 0.51, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioNTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNTech is expected to be smaller as well. Please check BioNTech's standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to make a quick decision on whether BioNTech's price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain essential indicators, BioNTech disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Ex Dividend Date 2022-06-06 |
1 | PFE BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab - Zacks Investment Research | 09/23/2024 |
2 | BioNTech SE ADR falls Monday, still outperforms market - MarketWatch | 10/07/2024 |
3 | BioNTechs SWOT analysis oncology pipeline fuels stocks potential amid market volatility - Investing.com | 11/21/2024 |
| Begin Period Cash Flow | 13.9 B |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 8,778 in BioNTech SE on September 1, 2024 and sell it today you would earn a total of 3,222 from holding BioNTech SE or generate 36.71% return on investment over 90 days. BioNTech SE is generating 0.5501% of daily returns and assumes 3.9731% volatility on return distribution over the 90 days horizon. Simply put, 35% of stocks are less volatile than BioNTech, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1385
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 0A3M | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.97 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.55 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average BioNTech is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding it to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.48 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 11.68 B | ||||
| Shares Outstanding | 239.77 M | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 3.59 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 5.94 B | ||||
| Net Income | 930.3 M | ||||
| Cash And Equivalents | 914.9 M | ||||
| Cash Per Share | 3.75 X | ||||
| Total Debt | 28.1 M | ||||
| Debt To Equity | 0.05 % | ||||
| Book Value Per Share | 83.02 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Earnings Per Share | 18.00 X | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
About BioNTech Performance
By examining BioNTech's fundamental ratios, stakeholders can obtain critical insights into BioNTech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BioNTech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people.Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE appears to be risky and price may revert if volatility continues | |
| About 65.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: BioNTechs SWOT analysis oncology pipeline fuels stocks potential amid market volatility - Investing.com |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.